GB201512369D0 - Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Info

Publication number
GB201512369D0
GB201512369D0 GBGB1512369.8A GB201512369A GB201512369D0 GB 201512369 D0 GB201512369 D0 GB 201512369D0 GB 201512369 A GB201512369 A GB 201512369A GB 201512369 D0 GB201512369 D0 GB 201512369D0
Authority
GB
United Kingdom
Prior art keywords
peptides
cancers
combination
ovarian cancer
epithelial ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1512369.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1512369.8A priority Critical patent/GB201512369D0/en
Priority to MYPI2018700111A priority patent/MY189596A/en
Publication of GB201512369D0 publication Critical patent/GB201512369D0/en
Priority to SG10202100295RA priority patent/SG10202100295RA/en
Priority to JP2018501316A priority patent/JP6862411B2/ja
Priority to IL308200A priority patent/IL308200A/en
Priority to ES16739102T priority patent/ES2807832T3/es
Priority to CR20200410A priority patent/CR20200410A/es
Priority to CR20200409A priority patent/CR20200409A/es
Priority to MA42441A priority patent/MA42441B1/fr
Priority to UAA201712985A priority patent/UA124875C2/uk
Priority to PT167391028T priority patent/PT3322717T/pt
Priority to PL16739102T priority patent/PL3322717T3/pl
Priority to HRP20201281TT priority patent/HRP20201281T1/hr
Priority to SG10202100291XA priority patent/SG10202100291XA/en
Priority to KR1020227017673A priority patent/KR20220075451A/ko
Priority to EP16739102.8A priority patent/EP3322717B1/en
Priority to SG10202100294WA priority patent/SG10202100294WA/en
Priority to CR20180027A priority patent/CR20180027A/es
Priority to MA41717A priority patent/MA41717A1/fr
Priority to CN201680041146.8A priority patent/CN107922469A/zh
Priority to CR20200408A priority patent/CR20200408A/es
Priority to BR122023024959-3A priority patent/BR122023024959A2/pt
Priority to SG10202100296PA priority patent/SG10202100296PA/en
Priority to NZ739128A priority patent/NZ739128A/en
Priority to DK16739102.8T priority patent/DK3322717T3/da
Priority to HK18112779.2A priority patent/HK1253574B/en
Priority to SG10202100297QA priority patent/SG10202100297QA/en
Priority to PE2023001339A priority patent/PE20240645A1/es
Priority to MX2018000543A priority patent/MX2018000543A/es
Priority to IL292131A priority patent/IL292131A/en
Priority to LTEP16739102.8T priority patent/LT3322717T/lt
Priority to PE2018000052A priority patent/PE20180693A1/es
Priority to KR1020187000652A priority patent/KR20180030506A/ko
Priority to MEP-2020-159A priority patent/ME03808B/me
Priority to BR112017028558-4A priority patent/BR112017028558A2/pt
Priority to PCT/EP2016/066706 priority patent/WO2017009400A1/en
Priority to AU2016293047A priority patent/AU2016293047B9/en
Priority to CN202111534523.0A priority patent/CN114163501A/zh
Priority to SI201630868T priority patent/SI3322717T1/sl
Priority to MA050542A priority patent/MA50542A/fr
Priority to CA2992506A priority patent/CA2992506A1/en
Priority to SG10202100298SA priority patent/SG10202100298SA/en
Priority to CA3221097A priority patent/CA3221097A1/en
Priority to HUE16739102A priority patent/HUE049937T2/hu
Priority to US15/209,845 priority patent/US9889159B2/en
Priority to EP20170212.3A priority patent/EP3705491A1/en
Priority to SG10202100292VA priority patent/SG10202100292VA/en
Priority to RS20200937A priority patent/RS60647B1/sr
Priority to MDE20180524T priority patent/MD3322717T2/ro
Priority to EA201890027A priority patent/EA201890027A1/ru
Priority to US15/813,610 priority patent/US10463696B2/en
Priority to IL256697A priority patent/IL256697B/en
Priority to PH12018500005A priority patent/PH12018500005A1/en
Priority to ZA2018/00129A priority patent/ZA201800129B/en
Priority to MX2023014146A priority patent/MX2023014146A/es
Priority to CONC2018/0000252A priority patent/CO2018000252A2/es
Priority to CL2018000124A priority patent/CL2018000124A1/es
Priority to US16/556,549 priority patent/US10639331B2/en
Priority to US16/556,704 priority patent/US10639332B2/en
Priority to US16/556,695 priority patent/US10568909B2/en
Priority to CL2019003312A priority patent/CL2019003312A1/es
Priority to CL2019003313A priority patent/CL2019003313A1/es
Priority to CL2019003310A priority patent/CL2019003310A1/es
Priority to CL2019003311A priority patent/CL2019003311A1/es
Priority to US16/777,919 priority patent/US10722538B2/en
Priority to JP2020052558A priority patent/JP7074367B2/ja
Priority to JP2020059702A priority patent/JP7239992B2/ja
Priority to JP2020068264A priority patent/JP7074369B2/ja
Priority to JP2020071602A priority patent/JP7074370B2/ja
Priority to JP2020074570A priority patent/JP7239993B2/ja
Priority to JP2020078116A priority patent/JP2020182458A/ja
Priority to JP2020082964A priority patent/JP2020198875A/ja
Priority to JP2020086514A priority patent/JP7205919B2/ja
Priority to JP2020090207A priority patent/JP2021000078A/ja
Priority to AU2020203971A priority patent/AU2020203971B2/en
Priority to US16/905,499 priority patent/US10869897B2/en
Priority to US16/905,530 priority patent/US10881690B2/en
Priority to US16/905,550 priority patent/US10888587B2/en
Priority to CY20201100848T priority patent/CY1123505T1/el
Priority to AU2020256318A priority patent/AU2020256318A1/en
Priority to US17/116,635 priority patent/US11071756B2/en
Priority to US17/123,585 priority patent/US20210106624A1/en
Priority to US17/245,076 priority patent/US11278571B2/en
Priority to US17/245,031 priority patent/US11806366B2/en
Priority to US17/245,105 priority patent/US11246889B2/en
Priority to US17/245,012 priority patent/US20210252064A1/en
Priority to US17/245,133 priority patent/US11819518B2/en
Priority to AU2022200745A priority patent/AU2022200745B2/en
Priority to US18/047,234 priority patent/US20230241106A1/en
Priority to US18/047,236 priority patent/US20230241107A1/en
Priority to US18/047,195 priority patent/US20230190813A1/en
Priority to US18/048,796 priority patent/US20230201259A1/en
Priority to US18/048,489 priority patent/US20230285458A1/en
Priority to US18/049,105 priority patent/US20230086100A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
GBGB1512369.8A 2015-07-15 2015-07-15 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers Ceased GB201512369D0 (en)

Priority Applications (94)

Application Number Priority Date Filing Date Title
GBGB1512369.8A GB201512369D0 (en) 2015-07-15 2015-07-15 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
MYPI2018700111A MY189596A (en) 2015-07-15 2015-07-15 A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100295RA SG10202100295RA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
JP2018501316A JP6862411B2 (ja) 2015-07-15 2016-07-14 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
IL308200A IL308200A (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial cancer and other cancers
ES16739102T ES2807832T3 (es) 2015-07-15 2016-07-14 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CR20200410A CR20200410A (es) 2015-07-15 2016-07-14 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
CR20200409A CR20200409A (es) 2015-07-15 2016-07-14 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
MA42441A MA42441B1 (fr) 2015-07-15 2016-07-14 Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
UAA201712985A UA124875C2 (uk) 2015-07-15 2016-07-14 Пептид для застосування в імунотерапії епітеліального раку яєчника та інших видів раку
PT167391028T PT3322717T (pt) 2015-07-15 2016-07-14 Novos péptidos e combinação de péptidos para utilização em imunoterapia contra cancro do ovário epitelial e outros cancros
PL16739102T PL3322717T3 (pl) 2015-07-15 2016-07-14 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem nabłonkowego raka jajnika i innych rodzajów raka
HRP20201281TT HRP20201281T1 (hr) 2015-07-15 2016-07-14 Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
SG10202100291XA SG10202100291XA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
KR1020227017673A KR20220075451A (ko) 2015-07-15 2016-07-14 상피 난소암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
EP16739102.8A EP3322717B1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100294WA SG10202100294WA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CR20180027A CR20180027A (es) 2015-07-15 2016-07-14 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MA41717A MA41717A1 (fr) 2015-07-15 2016-07-14 Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
CN201680041146.8A CN107922469A (zh) 2015-07-15 2016-07-14 用于上皮性卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
CR20200408A CR20200408A (es) 2015-07-15 2016-07-14 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
BR122023024959-3A BR122023024959A2 (pt) 2015-07-15 2016-07-14 Peptídeo, receptor de célula t, anticorpo, linfócito t ativado, bem como métodos para produzi-los, ácido nucleico, célula hospedeira recombinante, composição farmacêutica, uso e kit
SG10202100296PA SG10202100296PA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
NZ739128A NZ739128A (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
DK16739102.8T DK3322717T3 (da) 2015-07-15 2016-07-14 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod epitelial ovariecancer og andre cancere
HK18112779.2A HK1253574B (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100297QA SG10202100297QA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
PE2023001339A PE20240645A1 (es) 2015-07-15 2016-07-14 Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
MX2018000543A MX2018000543A (es) 2015-07-15 2016-07-14 Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer.
IL292131A IL292131A (en) 2015-07-15 2016-07-14 Innovative peptides and a combination of peptides for use in immunotherapy against epithelial ovarian cancer and other types of cancer
LTEP16739102.8T LT3322717T (lt) 2015-07-15 2016-07-14 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš epitelinį kiaušidžių vėžį ir kitų rūšių vėžį
PE2018000052A PE20180693A1 (es) 2015-07-15 2016-07-14 Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer
KR1020187000652A KR20180030506A (ko) 2015-07-15 2016-07-14 상피 난소암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
MEP-2020-159A ME03808B (me) 2015-07-15 2016-07-14 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore
BR112017028558-4A BR112017028558A2 (pt) 2015-07-15 2016-07-14 peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer epitelial de ovário e outros cânceres
PCT/EP2016/066706 WO2017009400A1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
AU2016293047A AU2016293047B9 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CN202111534523.0A CN114163501A (zh) 2015-07-15 2016-07-14 用于上皮性卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
SI201630868T SI3322717T1 (sl) 2015-07-15 2016-07-14 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti epitelijskemu raku jajčnikov in drugim oblikam raka
MA050542A MA50542A (fr) 2015-07-15 2016-07-14 Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
CA2992506A CA2992506A1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100298SA SG10202100298SA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CA3221097A CA3221097A1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
HUE16739102A HUE049937T2 (hu) 2015-07-15 2016-07-14 Új peptidek és peptidkombinációk az epiteliális petefészekrák és más ráktípusok elleni immunterápiában történõ használatra
US15/209,845 US9889159B2 (en) 2015-07-15 2016-07-14 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
EP20170212.3A EP3705491A1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202100292VA SG10202100292VA (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
RS20200937A RS60647B1 (sr) 2015-07-15 2016-07-14 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore
MDE20180524T MD3322717T2 (ro) 2015-07-15 2016-07-14 Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului ovarian epitelial și a altor cancere
EA201890027A EA201890027A1 (ru) 2015-07-15 2016-07-14 Новые пептиды и комбинации пептидов для применения в иммунотерапии эпителиального рака яичника и других видов рака
US15/813,610 US10463696B2 (en) 2015-07-15 2017-11-15 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
IL256697A IL256697B (en) 2015-07-15 2018-01-02 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
PH12018500005A PH12018500005A1 (en) 2015-07-15 2018-01-03 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
ZA2018/00129A ZA201800129B (en) 2015-07-15 2018-01-08 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
MX2023014146A MX2023014146A (es) 2015-07-15 2018-01-12 Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer.
CONC2018/0000252A CO2018000252A2 (es) 2015-07-15 2018-01-12 Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CL2018000124A CL2018000124A1 (es) 2015-07-15 2018-01-15 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
US16/556,549 US10639331B2 (en) 2015-07-15 2019-08-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US16/556,704 US10639332B2 (en) 2015-07-15 2019-08-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US16/556,695 US10568909B2 (en) 2015-07-15 2019-08-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CL2019003312A CL2019003312A1 (es) 2015-07-15 2019-11-19 Nuevos péptidos (seq id no:122) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer.(divisional solicitud 201800124)
CL2019003313A CL2019003313A1 (es) 2015-07-15 2019-11-19 Nuevos péptidos (seq id no:128) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
CL2019003310A CL2019003310A1 (es) 2015-07-15 2019-11-19 Nuevos péptidos (seq id no:1) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
CL2019003311A CL2019003311A1 (es) 2015-07-15 2019-11-19 Nuevos péptidos (seq id no:82) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
US16/777,919 US10722538B2 (en) 2015-07-15 2020-01-31 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
JP2020052558A JP7074367B2 (ja) 2015-07-15 2020-03-24 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020059702A JP7239992B2 (ja) 2015-07-15 2020-03-30 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020068264A JP7074369B2 (ja) 2015-07-15 2020-04-06 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020071602A JP7074370B2 (ja) 2015-07-15 2020-04-13 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020074570A JP7239993B2 (ja) 2015-07-15 2020-04-20 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020078116A JP2020182458A (ja) 2015-07-15 2020-04-27 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020082964A JP2020198875A (ja) 2015-07-15 2020-05-11 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020086514A JP7205919B2 (ja) 2015-07-15 2020-05-18 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020090207A JP2021000078A (ja) 2015-07-15 2020-05-25 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
AU2020203971A AU2020203971B2 (en) 2015-07-15 2020-06-15 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US16/905,499 US10869897B2 (en) 2015-07-15 2020-06-18 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US16/905,530 US10881690B2 (en) 2015-07-15 2020-06-18 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US16/905,550 US10888587B2 (en) 2015-07-15 2020-06-18 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CY20201100848T CY1123505T1 (el) 2015-07-15 2020-09-08 Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του επιθηλιακου καρκινου των ωοθηκων και αλλων καρκινων
AU2020256318A AU2020256318A1 (en) 2015-07-15 2020-10-13 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/116,635 US11071756B2 (en) 2015-07-15 2020-12-09 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/123,585 US20210106624A1 (en) 2015-07-15 2020-12-16 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/245,076 US11278571B2 (en) 2015-07-15 2021-04-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/245,031 US11806366B2 (en) 2015-07-15 2021-04-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/245,105 US11246889B2 (en) 2015-07-15 2021-04-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/245,012 US20210252064A1 (en) 2015-07-15 2021-04-30 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US17/245,133 US11819518B2 (en) 2015-07-15 2021-04-30 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
AU2022200745A AU2022200745B2 (en) 2015-07-15 2022-02-04 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US18/047,234 US20230241106A1 (en) 2015-07-15 2022-10-17 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US18/047,236 US20230241107A1 (en) 2015-07-15 2022-10-17 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US18/047,195 US20230190813A1 (en) 2015-07-15 2022-10-17 Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US18/048,796 US20230201259A1 (en) 2015-07-15 2022-10-21 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US18/048,489 US20230285458A1 (en) 2015-07-15 2022-10-21 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US18/049,105 US20230086100A1 (en) 2015-07-15 2022-10-24 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512369.8A GB201512369D0 (en) 2015-07-15 2015-07-15 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Publications (1)

Publication Number Publication Date
GB201512369D0 true GB201512369D0 (en) 2015-08-19

Family

ID=54013984

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1512369.8A Ceased GB201512369D0 (en) 2015-07-15 2015-07-15 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Country Status (36)

Country Link
US (22) US9889159B2 (enExample)
EP (2) EP3705491A1 (enExample)
JP (10) JP6862411B2 (enExample)
KR (2) KR20220075451A (enExample)
CN (2) CN107922469A (enExample)
AU (4) AU2016293047B9 (enExample)
BR (2) BR122023024959A2 (enExample)
CA (2) CA2992506A1 (enExample)
CL (5) CL2018000124A1 (enExample)
CO (1) CO2018000252A2 (enExample)
CR (4) CR20200408A (enExample)
CY (1) CY1123505T1 (enExample)
DK (1) DK3322717T3 (enExample)
EA (1) EA201890027A1 (enExample)
ES (1) ES2807832T3 (enExample)
GB (1) GB201512369D0 (enExample)
HR (1) HRP20201281T1 (enExample)
HU (1) HUE049937T2 (enExample)
IL (3) IL308200A (enExample)
LT (1) LT3322717T (enExample)
MA (3) MA50542A (enExample)
MD (1) MD3322717T2 (enExample)
ME (1) ME03808B (enExample)
MX (2) MX2018000543A (enExample)
MY (1) MY189596A (enExample)
NZ (1) NZ739128A (enExample)
PE (2) PE20240645A1 (enExample)
PH (1) PH12018500005A1 (enExample)
PL (1) PL3322717T3 (enExample)
PT (1) PT3322717T (enExample)
RS (1) RS60647B1 (enExample)
SG (7) SG10202100291XA (enExample)
SI (1) SI3322717T1 (enExample)
UA (1) UA124875C2 (enExample)
WO (1) WO2017009400A1 (enExample)
ZA (1) ZA201800129B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AU2018212584B2 (en) * 2017-01-27 2020-12-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
WO2020028562A1 (en) * 2018-07-31 2020-02-06 Loma Linda University Snail sirna-loaded mesoporous silica nanoparticles
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
DE102019108125B4 (de) * 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2022543687A (ja) * 2019-08-09 2022-10-13 イマティクス ユーエス，アイエヌシー． ペプチド質量分析断片化を予測するための方法
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4165059A1 (en) * 2020-06-13 2023-04-19 Complete Omics Inc. Method and system for neoantigen analysis
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN113241177B (zh) * 2021-05-19 2024-05-10 上海宝藤生物医药科技股份有限公司 一种评估免疫力水平的方法、装置、设备及存储介质
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4392441A1 (en) * 2021-08-24 2024-07-03 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
GB202302709D0 (en) * 2023-02-24 2023-04-12 Genome Res Ltd Method of identifying t cell recpetors of interest
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026096743A1 (en) 2024-10-30 2026-05-07 Immatics US, Inc. Methods for gamma delta t cells manufacturing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175625A1 (en) * 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004050860A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2005282489A1 (en) * 2004-09-08 2006-03-16 Cornell Research Foundation, Inc. Cancer-testis antigens
JP4987698B2 (ja) * 2005-03-31 2012-07-25 中外製薬株式会社 癌関連抗原アナログペプチド、およびその利用
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
US8097242B2 (en) 2006-10-05 2012-01-17 The Board Of Trustees Of The University Of Arkansas Target CA125 peptides for cancer immunotherapy
RS54204B1 (sr) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
WO2009032224A2 (en) * 2007-08-29 2009-03-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting squamous cell carcinoma
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2014011465A2 (en) * 2012-07-13 2014-01-16 Albert Einstein College Of Medicine Of Yeshiva University Aptamer-targeted antigen delivery
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
IL301919A (en) * 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Also Published As

Publication number Publication date
US11819518B2 (en) 2023-11-21
BR112017028558A2 (pt) 2018-09-04
US10568909B2 (en) 2020-02-25
US20200316126A1 (en) 2020-10-08
MX2018000543A (es) 2018-05-22
US10639332B2 (en) 2020-05-05
JP7205919B2 (ja) 2023-01-17
PE20240645A1 (es) 2024-04-04
JP7074370B2 (ja) 2022-05-24
AU2016293047B9 (en) 2020-10-29
EP3705491A1 (en) 2020-09-09
US20210260122A1 (en) 2021-08-26
JP2020182458A (ja) 2020-11-12
JP2018531581A (ja) 2018-11-01
SG10202100296PA (en) 2021-02-25
MY189596A (en) 2022-02-18
JP2020182451A (ja) 2020-11-12
US20210252064A1 (en) 2021-08-19
DK3322717T3 (da) 2020-08-10
JP6862411B2 (ja) 2021-04-21
CR20200409A (es) 2020-10-16
SG10202100297QA (en) 2021-02-25
US20190381103A1 (en) 2019-12-19
US20230241106A1 (en) 2023-08-03
CR20180027A (es) 2018-07-23
CA2992506A1 (en) 2017-01-19
CL2019003311A1 (es) 2020-03-13
JP2020171283A (ja) 2020-10-22
MA41717A1 (fr) 2019-05-31
CL2019003312A1 (es) 2020-03-13
MD3322717T2 (ro) 2020-11-30
US20200000849A1 (en) 2020-01-02
CR20200410A (es) 2020-10-12
BR122023024959A2 (pt) 2024-01-16
JP7239993B2 (ja) 2023-03-15
SG10202100294WA (en) 2021-02-25
MA50542A (fr) 2020-09-09
US20230086100A1 (en) 2023-03-23
JP7074369B2 (ja) 2022-05-24
JP7074367B2 (ja) 2022-05-24
MA42441B1 (fr) 2020-07-29
JP2021000078A (ja) 2021-01-07
JP7239992B2 (ja) 2023-03-15
ZA201800129B (en) 2018-12-19
PE20180693A1 (es) 2018-04-23
JP2020198875A (ja) 2020-12-17
SG10202100291XA (en) 2021-02-25
US20200155603A1 (en) 2020-05-21
RS60647B1 (sr) 2020-09-30
SG10202100298SA (en) 2021-02-25
AU2016293047B2 (en) 2020-09-17
EA201890027A1 (ru) 2018-06-29
HUE049937T2 (hu) 2020-11-30
AU2022200745B2 (en) 2024-01-18
CL2019003310A1 (es) 2020-04-24
US20210106624A1 (en) 2021-04-15
MX2023014146A (es) 2023-12-13
US10869897B2 (en) 2020-12-22
US20230285458A1 (en) 2023-09-14
JP2020127401A (ja) 2020-08-27
IL256697B (en) 2022-05-01
UA124875C2 (uk) 2021-12-08
US20230201259A1 (en) 2023-06-29
KR20220075451A (ko) 2022-06-08
US10888587B2 (en) 2021-01-12
US20210252065A1 (en) 2021-08-19
IL292131A (en) 2022-06-01
HK1253574A1 (en) 2019-06-21
LT3322717T (lt) 2020-08-25
CN114163501A (zh) 2022-03-11
HRP20201281T1 (hr) 2020-11-13
US20200316125A1 (en) 2020-10-08
JP2020167995A (ja) 2020-10-15
US20200316127A1 (en) 2020-10-08
PT3322717T (pt) 2020-07-27
US11246889B2 (en) 2022-02-15
US20210252066A1 (en) 2021-08-19
US10722538B2 (en) 2020-07-28
US20180117085A1 (en) 2018-05-03
ES2807832T3 (es) 2021-02-24
US11806366B2 (en) 2023-11-07
CA3221097A1 (en) 2017-01-19
CY1123505T1 (el) 2022-03-24
AU2016293047A1 (en) 2018-02-08
JP2020156480A (ja) 2020-10-01
EP3322717A1 (en) 2018-05-23
NZ739128A (en) 2022-04-29
SG10202100292VA (en) 2021-02-25
CO2018000252A2 (es) 2018-05-31
AU2020203971A1 (en) 2020-07-02
AU2020203971B2 (en) 2021-11-25
US20170035807A1 (en) 2017-02-09
US10881690B2 (en) 2021-01-05
WO2017009400A1 (en) 2017-01-19
US11278571B2 (en) 2022-03-22
US20210260123A1 (en) 2021-08-26
US20210106623A1 (en) 2021-04-15
US10639331B2 (en) 2020-05-05
US11071756B2 (en) 2021-07-27
IL256697A (en) 2018-03-29
KR20180030506A (ko) 2018-03-23
SG10202100295RA (en) 2021-02-25
JP2020191862A (ja) 2020-12-03
ME03808B (me) 2021-04-20
AU2022200745A1 (en) 2022-02-24
US20230241107A1 (en) 2023-08-03
US10463696B2 (en) 2019-11-05
US20230190813A1 (en) 2023-06-22
US9889159B2 (en) 2018-02-13
PL3322717T3 (pl) 2020-11-16
IL308200A (en) 2024-01-01
US20200000850A1 (en) 2020-01-02
AU2020256318A1 (en) 2020-11-12
CL2018000124A1 (es) 2018-05-18
CL2019003313A1 (es) 2020-03-13
EP3322717B1 (en) 2020-06-10
CR20200408A (es) 2020-10-08
PH12018500005A1 (en) 2018-07-09
SI3322717T1 (sl) 2020-09-30
AU2016293047A2 (en) 2018-03-15
CN107922469A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
ZA201800129B (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
ZA201707942B (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL268278A (en) New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG11201706155XA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
ZA201800513B (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201517538D0 (en) Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG10202005498VA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)